Table of Contents
Introduction
Global Coronary Stents Market size is expected to be worth around US$ 24.0 Billion by 2032 from US$ 13.4 Billion in 2023, growing at a CAGR of 6.9% during the forecast period from 2023 to 2032. In 2023, North America led the market, achieving over 39.4% share with a revenue of US$ 4.0 Million.
The coronary stents market is experiencing notable growth due to several key factors. One major driver is the rising prevalence of coronary artery disease (CAD), which impacts millions globally and remains a leading cause of death. This surge in heart disease has increased the demand for effective treatments, with stents playing a critical role in percutaneous coronary interventions (PCI) to restore proper blood flow to the heart.
Technological advancements have also significantly propelled market growth. Drug-eluting stents, which release medication to prevent artery re-narrowing, represent a pivotal innovation. Additionally, breakthroughs like fully absorbable stents, such as the Absorb GT1 Bioresorbable Vascular Scaffold System, continue to enhance stent technology. These advancements focus on improving patient outcomes by minimizing complications, including restenosis and blood clots.
Furthermore, the aging population has boosted the demand for coronary interventions. Older adults, who are more vulnerable to cardiovascular diseases, benefit greatly from stenting as it improves their quality of life, particularly for those experiencing symptoms like chest pain. The essential role of coronary stents in modern cardiology underscores their growing importance in the expanding market.
Key Takeaways
- Market Size: The Global Coronary Stents Market size is expected to be worth around USD 24.0 Billion by 2032 from USD 13.4 Billion in 2023.
- Market Growth: The Global Coronary Stents Market is growing at a CAGR of 6.9% during the forecast period from 2024 to 2032.
- Product Analysis: A bioabsorbable segment is expected to witness the highest growth during the forecast period.
- Development Analysis: The estimated dominance of self-expanding stents in the market is primarily due to clinically proven and emerging local and regional manufacturers worldwide.
- End-User Analysis: Hospital Segment Dominating the Global Coronary Stents Market Size
- Regional Analysis: With a share of 39.4%, North America dominated the coronary stent market and contributed the most revenue.
- Increasing Demand: The rising prevalence of cardiovascular diseases, an aging population, and a growing preference for minimally invasive procedures are driving the demand for coronary stents.
- Innovative Developments: Recent developments include Medtronic’s launch of the Onyx Frontier stent in Europe and its subsequent FDA approval in the U.S. These stents are designed to enhance deliverability and performance.
- Challenges: The market faces several challenges, including cost constraints in developing regions, post-procedural complications, and stringent regulatory requirements.
Coronary Stents Statistics
- Coronary Artery Disease Prevalence: Approximately 18 million Americans are affected by coronary artery disease, making it the leading cause of death in the United States.
- Stent Usage: Each year, around 1 million coronary stents are implanted in the United States.
- Types of Stents: The two main types of stents used in coronary procedures are bare-metal stents and drug-eluting stents.
- Effectiveness: Drug-eluting stents reduce the risk of restenosis (artery re-narrowing) by approximately 50% compared to bare-metal stents.
- Restenosis Rate: Bare-metal stents have a restenosis rate of 20-30%, while drug-eluting stents lower this to less than 10%.
- Stent Thrombosis: Stent thrombosis, a serious complication, occurs in about 0.5-2.0% of patients receiving stents.
- Survival Rate: For stable ischemic heart disease, no significant survival difference is observed between patients treated with stents and those treated with medication and lifestyle changes.
- Quality of Life: Stenting and bypass surgery offer better symptom relief and quality-of-life improvements for patients with chest pain compared to medication alone.
- Recovery: Most patients resume normal activities within a week of undergoing coronary stenting.
- Follow-up Care: Dual antiplatelet therapy (DAPT) is typically required for 6-12 months post-stent placement to prevent blood clots.
- Antiplatelet Therapy: Long-term antiplatelet use post-stenting reduces the risk of heart attack and death by 20-30%.
- Coronary Artery Disease Risk Factors: High blood pressure, high cholesterol, smoking, and diabetes are key risk factors for coronary artery disease.
- Gender Disparity: Men have a higher risk of coronary artery disease than women until menopause, after which women’s risk increases.
- Global Impact: Cardiovascular diseases, including those requiring stents, cause around 17.9 million deaths annually worldwide.
Company Analysis
- Abbott: In July 2024, Abbott launched its next-generation XIENCE drug-eluting stents with improved delivery systems for complex anatomies, aiming to enhance patient outcomes.
- Medtronic: In June 2024, Medtronic expanded its portfolio with the Resolute Onyx drug-eluting stent in Asia, incorporating CoreWire technology for superior flexibility and conformability.
- Boston Scientific Corporation: In August 2024, Boston Scientific introduced the Synergy XD Bioabsorbable Polymer Drug-Eluting Stent System in Europe, enhancing drug elution and vessel healing.
- Terumo Corporation: In May 2024, Terumo acquired a novel stent technology from a European firm, broadening its interventional cardiology product portfolio.
- B. Braun Melsungen AG: In July 2024, B. Braun unveiled new coronary stents featuring advanced coating technology to reduce restenosis and improve patient outcomes.
- Biotronik: In March 2024, Biotronik launched the Orsiro Mission Drug-Eluting Stent in the U.S., offering superior deliverability and long-term safety.
- Stentys SA: In April 2024, Stentys merged with a leading European cardiovascular device company to expand market reach and strengthen its coronary stent product line.
Emerging Trends in the Coronary Stents Market
- Technological Advancements: Drug-eluting stents (DES) with advanced polymer coatings improve drug release, reduce clot formation, and minimize restenosis. Innovations in biocompatible materials and enhanced delivery systems enhance patient safety and efficacy, solidifying DES as a preferred choice.
- Bioabsorbable Stents: Bioabsorbable stents dissolve after use, restoring natural vessel flexibility and reducing risks associated with permanent implants. By leaving behind a healed artery, they decrease complications like late stent thrombosis and address long-term intervention challenges.
- Minimally Invasive Procedures: Percutaneous coronary interventions (PCI) are increasingly favored for their smaller incisions, quicker recovery, less pain, and lower infection risks compared to open-heart surgeries. This trend reflects a broader shift toward minimally invasive healthcare.
- Focus on Personalized Medicine: Tailored stent designs based on individual patient needs enhance treatment success and reduce adverse effects. Adjustments in stent size, drug formulation, and release rates emphasize the growing importance of personalized care in cardiology.
- Integration with Digital Health: Stents embedded with smart sensors enable real-time monitoring of stent performance and vascular health. These technologies support remote management of cardiovascular conditions, fostering a connected and proactive healthcare system.
- Regulatory Approvals: Regulatory clearances, such as FDA approvals, ensure that new stent designs meet rigorous safety and efficacy standards. These validations drive innovation, introducing advanced delivery mechanisms and safer technologies to benefit patients.
- Focus on Cost-effectiveness: Initiatives to reduce stent costs, such as local manufacturing and bulk purchasing, improve affordability and access, particularly in developing regions. This focus helps address healthcare disparities and expand treatment availability.
- Increased Use of Imaging Techniques: Imaging methods like intravascular ultrasound (IVUS) and optical coherence tomography (OCT) enhance precision during stent placement. These tools ensure optimal positioning, minimize complications, and improve long-term outcomes.
Use Cases of Coronary Stents
- Angina Relief: Stents restore blood flow in blocked arteries, relieving chest pain and significantly improving patients’ daily lives and long-term heart health.
- Heart Attack Treatment: During heart attacks, stents rapidly open blocked arteries, minimizing heart damage, improving survival rates, and supporting better recovery outcomes.
- Post-Bypass Surgery: For patients experiencing new blockages after coronary artery bypass grafting (CABG), stents maintain blood flow, extending the benefits of the initial surgery and preventing symptom recurrence.
- Coronary Artery Disease Management: Stents help manage CAD by keeping arteries open after angioplasty, reducing heart attack risks and improving long-term prognosis when medication is insufficient.
- Minimally Invasive Alternative: Compared to CABG, stenting offers a less invasive option with shorter hospital stays, faster recovery times, and fewer complications, enhancing patient satisfaction.
- Recurrent Blockage Prevention: Drug-eluting stents release medication to prevent restenosis, reducing the likelihood of repeat procedures and ensuring long-term arterial health.
- Improving Quality of Life: By alleviating chest pain and improving heart function, stents enable patients with ischemic heart disease to lead more active and fulfilling lives.
- High-Risk Patients: Stenting offers a safer alternative for high-risk patients unsuitable for open-heart surgery, reducing complications and overall treatment risks.
- Immediate Intervention: In acute coronary syndrome (ACS), stents quickly restore blood flow, preventing further heart damage and supporting a faster recovery.
Conclusion
The coronary stents market is poised for significant growth, driven by the rising prevalence of coronary artery disease, advancements in stent technology, and increasing demand for minimally invasive procedures. Innovations such as drug-eluting and bioabsorbable stents, coupled with a focus on personalized medicine, enhance patient outcomes and expand treatment options.
Aging populations and a growing preference for PCI further boost demand, while regulatory approvals and cost-effectiveness initiatives improve accessibility. Despite challenges like cost constraints and regulatory hurdles, the market’s trajectory is promising, underscored by ongoing technological advancements and a critical role in managing cardiovascular diseases worldwide.
Discuss your needs with our analyst
Please share your requirements with more details so our analyst can check if they can solve your problem(s)
